WBC - Le futur a un avenir !
12 views | +0 today
Your new post is loading...
Your new post is loading...
Rescooped by Eric Louis Poskin from Doctors Hub

37 Startups building voice applications for healthcare

As the next frontier in human-technology interfaces, voice-enabled and voice-first technologies are leading the way in many innovative applications across industries.
Via Philippe Marchal
No comment yet.
Rescooped by Eric Louis Poskin from Pharma Biotech Industry Review (Krishan Maggon)

CEFALY® for treatment and prevention of migraines and tension headaches

CEFALY® for treatment and prevention of migraines and tension headaches | WBC - Le futur a un avenir ! | Scoop.it

STX-Med’s mission is to research and develop practical innovations for use on humans in the field of electronics and bio-electronics. STX-Med produces CEFALY a medical device for treatement and prevention of migraines and headaches


Drug-Free Migraine Treatment CEFALY®: Publication of a Study Conducted on 2,313 PatientsThe scientific journal "JOURNAL of HEADACHE and PAIN" publishes positive results from a clinical study conducted on 2,313 patients which confirms the high efficacy and safety of the medical device CEFALY ® migraine treatment.


The efficacy and safety of the CEFALY ® medical device for migraine treatment had already been reported early 2013 in the scientific journal "Neurology" (Official Journal of the American Academy of Neurology). Today published data on a large number of individuals confirm the significant improvement for a majority of patients. Following 2 months of treatment, 54.4% of the patients described a very substantial improvement and decided to purchase the device. If we rule out those patients who didn't use the device or who only used it to a negligible degree, and take into account only regular users, the percentage of patients with a very significant improvement reaches 81%. Side effects are reported by only 4.3% of patients, all of which are minor and completely reversible. Therefore the effectiveness/safety ratio is excellent.

Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly ® is therefore a means of choice to treat a majority of migraine patients.


Cefaly® is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to pacemakers). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.

A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.


The Cefaly® medical device is available on the European market and in Canada and now in the US.


The results show the effectiveness of Cefaly® in the reduction of migraines. By the third month of treatment, a statistically significant difference is observed in the percentage of responders in the Cefaly® group compared to the placebo group. The percentage of patients who states they were satisfied or very satisfied by the treatment with Cefaly® was almost 70%. The reduction in consumption of medications is particularly impressive, since it fell by 37% in the group treated with Cefaly®, whereas it remained virtually unchanged in the placebo group. In the group of responders to Cefaly®, the reduction in the consumption of medication was almost 75%. Moreover, the lack of side effects and contraindications means that Cefaly is an extremely safe therapeutic method, unlike classic drug-based methods. Offering comparable effectiveness but with complete safety, Cefaly® therefore boasts and excellent safety and effectiveness profile.


Previously, the sedative effect of Cefaly was demonstrated by another recent study, the results of which were published in the journal BMC Neurology: http://www.ncbi.nlm.nih.gov/pubmed/22035386

Via Krishan Maggon
Krishan Maggon 's curator insight, March 12, 2014 2:56 AM

Cefaly sales in Europe have been brisk and increased by over 30% in 2013.